Wednesday December 18, 2013 0 comments
DENVER - Colorado bioscience companies realized a number of key financings and acquisitions in 2013, according to the Colorado BioScience Association, an industry support group.
"We saw several exciting deals this year with many more on the horizon as Colorado continues to gain national recognition in the bioscience industry," said April Giles, CBSA president and CEO.
Financing and acquisition deals over $8 million in 2013 included:
- Boulder-based Biodesix closing an $8.8M Series D financing in April
- Fort Collins-based Inviragen agreeing to be acquired by Japan-based Takeda for $250 million in May
- Broomfield-based Lanx Inc. completing a $15 million Series C equity financing in May.
- Boulder-based Clovis Oncology raising an additional $275 million in June
- Boulder-based SomaLogic raising $10 million in equity financing in August
- Lakewood-based Gambro BCT acquired by Illinois-based Baxter International for $4 billion in September
- Greenwood Vilalge0-based Ampio Pharmaceuticals announced a $25 million financing in September
- Westminster-based Surefire Medical closed in $18.2 million Series B funding in November
"Large financings and acquisitions are key to raising Colorado's profile to garner attention from investors and corporate leadership," Giles said.
"Colorado has all the pieces in place to be in the top 5 national bioscience clusters in the country - the science, the infrastructure and the people."